|1.||Wickstrom, Eric: 2 articles (01/2010 - 12/2007)|
|2.||Thakur, Mathew L: 2 articles (01/2010 - 12/2007)|
|3.||Zhang, Kaijun: 2 articles (01/2010 - 12/2007)|
|4.||Jensen, Robert T: 2 articles (01/2005 - 01/2004)|
|5.||Moody, Terry W: 2 articles (12/2004 - 01/2004)|
|6.||Aidil-Carvalho, Maria de Fatima: 1 article (11/2014)|
|7.||Cunha-Reis, Diana: 1 article (11/2014)|
|8.||Ribeiro, Joaquim A: 1 article (11/2014)|
|9.||Crevenna, Richard: 1 article (01/2013)|
|10.||Sun, Terri: 1 article (01/2013)|
01/01/2010 - "The 2 benign tumors that did not express the VPAC1 receptor were not imaged. "
01/30/2004 - "Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer."
04/15/1997 - "Because VIP-1 receptors appear to be expressed in the majority of neoplastic pancreatic duct cell lines and VIP stimulates growth of VIP-1 receptor-bearing Capan-2 cells in vitro, this peptide may well play an important role in the pathophysiology of tumors expressing these receptors in vivo."
01/01/2013 - "The VPAC1 receptor, a member of the vasoactive intestinal peptide receptors (VIPRs), is overexpressed in the most frequently occurring malignant tumors and plays a major role in the progression and angiogenesis of a number of malignancies. "
10/01/2011 - "Twenty-one percent of the tumor samples expressed only the VPAC1 receptor and 16% displayed only the VPAC2 receptor, while 13 samples (30%) expressed neither subtype. "
|2.||Breast Neoplasms (Breast Cancer)
12/04/2007 - "RT-PCR confirmed increased VPAC1 receptor expression on human breast tumor cells over normal cells and corroborated with autoradiography data. "
12/11/1998 - "Therefore VIP1 receptors may be utilized for the early detection and treatment of breast cancer."
12/11/1998 - "VIP1 receptors are present in breast cancer cells. "
01/02/2012 - "RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells."
02/15/2002 - "We have discovered a cellular receptor, VPAC1, that is a novel and potent facilitator of HIV-1 infection and thus, is a potentially important new target for therapeutic intervention."
05/01/2011 - "Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections."
|4.||Esophageal Achalasia (Megaesophagus)
09/01/2010 - "Recently, a single nucleotide polymorphism (SNP) of the vasoactive intestinal peptide receptor 1 (VIPR1) gene has been linked to late onset of achalasia, a lower esophagus dysmotility disorder. "
06/01/2009 - "Age-dependent association of idiopathic achalasia with vasoactive intestinal peptide receptor 1 gene."
|5.||Colonic Neoplasms (Colon Cancer)
05/01/2000 - "We previously showed that the expression of the VPAC1 receptor binding site is strictly dependent upon the enterocytic differentiation of human colon cancer Caco-2 cells [Laburthe, Rousset, Rouyer-Fessard, Couvineau, Chantret, Chevalier and Zweibaum (1987) J. "
05/05/1999 - "VIP receptors were found in 14/26 gastric and 23/25 colonic cancers; subtype characterization suggests VIP1 receptors. "
|1.||Messenger RNA (mRNA)
|2.||Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)
|3.||Type II Vasoactive Intestinal Peptide Receptors
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
|7.||Immune Sera (Antisera)